Ferroptosis Promotes Pulmonary Hypertension

• Published in: bioRxiv
• Main Authors: Vogel, Neal T, Annis, Jeffrey, Prisco, Sasha, Mancripe, Natalia Laixto, Blake, Madelyn, Brittain, Evan L, Prins, Kurt, Kazmirczak, Felipe
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 02.12.2023
• Subjects: Aging; Arteriosclerosis; Cardiovascular diseases; Cell death; Endothelial cells; Ferroptosis; Homeostasis; Hypertension; Iron; Ischemia; Lipid metabolism; Lung diseases; Mitochondria; Monocrotaline; Muscle contraction; Organelles; Oxidative stress; Phenotypes; Proteomics; Pulmonary hypertension; Sepsis; Vascular diseases
• DOI: 10.1101/2023.01.19.524721

Background: Mitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species (ROS) generation, results in lipid peroxidation-induced ferroptosis. Ferroptosis is an inflammatory mode of cell death as it both promotes complement activation and recruits macrophages. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit disrupted lipid metabolism and increased ROS production, and there is ectopic complement deposition and inflammatory macrophage accrual in the surrounding vasculature. However, the integrative effects of ferroptosis on metabolism, cellular landscape changes in the lung, complement induction, and pulmonary vascular remodeling are unknown. Methods: Multi-omics analyses in rodents and a genetic association study in humans evaluated the role of ferroptosis in PAH. Results: Ferrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity and improved right ventricular function in monocrotaline rats. RNA-seq and proteomics analyses demonstrated ferroptosis was induced with increasingly severe PAH. Metabolomics and proteomics data showed ferroptosis inhibition restructured lung metabolism and altered phosphatidylcholine and phosphatidylethanolamine levels. RNA-seq, proteomics, and confocal microscopy revealed complement activation and pro-inflammatory cytokines/chemokines were suppressed by ferrostatin-1. Additionally, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundances and gene activation patterns in the lungs as revealed by deconvolution RNA-seq. Finally, the presence of six single-nucleotide polymorphisms in ferroptosis genes were independently associated with pulmonary hypertension severity in the Vanderbilt BioVU repository. Conclusions: Rodent and human data nominate ferroptosis as a PAH regulating pathway via its ability to modulate lung lipid metabolism, repress pathogenic complement activation, dampen interstitial macrophage infiltration, and restore the lung cellular environment.Competing Interest StatementThe authors have declared no competing interest.Footnotes* We have updated the manuscript to be a much longer manuscript and we have included new data. We have uploaded supplemental data as well.